SCHEMBL1648272

SCHEMBL1648272

COC(=O)c1c(CS(=O)(=O)C2CCCCC2)ccc(-c2ccoc2)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.43
QRFPR Q96P65 1/20 0.34
PPARG P37231 1/20 0.33
NPC1 O15118 1/20 0.32
GAA P10253 1/20 0.32
SCN9A Q15858 1/20 0.32
FABP4 P15090 1/20 0.32
FABP5 Q01469 1/20 0.32
OPRM1 P35372 2/20 0.31
P2RX3 P56373 1/20 0.31
OPRK1 P41145 1/20 0.31
TUBB4A P04350 3/20 0.30
TUBB P07437 3/20 0.30
TUBA3C P0DPH7 3/20 0.30
TUBA1B P68363 3/20 0.30
TUBA4A P68366 3/20 0.30
TUBB4B P68371 3/20 0.30
TUBB3 Q13509 3/20 0.30
TUBB2A Q13885 3/20 0.30
TUBB8 Q3ZCM7 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647728 0.91 METAP2 (0.48) METAP2QRFPRPPARGSCN9AFABP4
SCHEMBL1648570 0.87 METAP2 (0.43) METAP2PPARGFABP4FABP5OPRM1
SCHEMBL1649059 0.83 METAP2 (0.43) METAP2PPARGFABP4FABP5OPRM1
SCHEMBL1648259 0.83 METAP2 (0.41) METAP2PPARGFABP4FABP5OPRM1
SCHEMBL1648298 0.83 METAP2 (0.42) METAP2PPARGFABP4FABP5OPRM1
SCHEMBL6844924 0.82 METAP2 (0.43) METAP2PPARGNPC1GAAALDH1A1
SCHEMBL6844926 0.81 METAP2 (0.43) METAP2PPARGNPC1FABP4FABP5
SCHEMBL18801187 0.81 ALDH1A1 (0.40) METAP2QRFPRPPARGNPC1OPRM1
SCHEMBL1648940 0.81 METAP2 (0.39) METAP2PPARGOPRM1
SCHEMBL1649232 0.79 SIGMAR1 (0.38) QRFPRNPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS METAP2 1/4885QRFPR 2903/4885PPARG 1735/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS METAP2 1/4885QRFPR 2903/4885PPARG 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.